Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 8, 2003, Pages 1455-1459

  Achan, Vinod ^c   Broadhead, Michael ^c   Malaki, Mohammed ^c   Whitley, Guy ^a   Leiper, James ^c   MacAllister, Raymond ^c   Vallance, Patrick ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NONE

Author keywords

Asymmetric methylarginine; Cardiac output; Dimethylarginine dimethylaminohydrolase; Hypertension; Nitric oxide

Indexed keywords

CITRULLINE; CREATININE; DIMETHYLAMINE; DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; EXERCISE; HAND GRIP; HEART OUTPUT; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; HYPOTHESIS; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; SYSTEMIC VASCULAR RESISTANCE;

ADULT; AMIDOHYDROLASES; ARGININE; BLOOD PRESSURE; CARDIAC OUTPUT; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; VASCULAR RESISTANCE;

EID: 0041733065     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000081742.92006.59     Document Type: Article

References (33)

1. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet. 2001;358:2096-2097.
2. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
3. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
4. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
5. Matsuoka H, Itoh S, Kimoto M, Kohno K. Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242-247.
6. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146.
7. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117.
8. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998;62:2425-2430.
9. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, Arnold JM. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res. 1998;37:667-675.
10. Ohnishi M, Wada A, Tsutamoto T, Fujii M, Matsumoto T, Yamamoto T, Takayama T, Wang X, Kinoshita M. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci. 2002;103(suppl 1):241S-244S.
11. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Boger R. Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine in hemodialysis patients. Kidney Int. 2002;62:339-345.
12. Charloux A. Lonsdorfer-Wolf E, Richard R, Lampert E, Oswald-Mammosser M, Mettauer B. Geny B, Lonsdorfer J. A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the direct Fick method. Eur J Appl Physiol. 2000;82:313-320.
13. Beal DD, Bryan GT. Quantitative spectrophotometric determination of human and rat urinary dimethylamine. Biochem Med. 1978;19:374-382.
14. Heinegard D, Tiderstrom G. Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta. 1973;43:305-310.
15. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338:1557-1558.
16. Haynes WG, Noon JP, Walker BR, Webb DJ. L-NMMA increases blood pressure in man. Lancet. 1993;342:931-932.
17. Cardounel AJ, Xia Y, Zweier JL. Different effects of endogenous nitric oxide synthase inhibitors on nitric oxide and superoxide production. Circulation. 2000;102:II-117. Abstract.
18. Sarkar D, Vallance P, Harding SE. Nitric oxide: not just a negative inotrope. Eur J Heart Fail. 2001;3:527-534.
19. Hogan N, Casadei B, Paterson DJ. Nitric oxide donors can increase heart rate independent of autonomic activation. J Appl Physiol. 1999;87:97-103.
20. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta: PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb. 1994;14:746-752.
21. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14:753-759.
22. Fickling SA, Leone AM, Nussey SS, Vallance P, Whitley GS. Synthesis of NG, NG dimethylarginine by human endothelial cells. Endothelium. 1993;1:137-140.
23. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol. 1994;112:43-48.
24. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun. 1987;148:671-677.
25. McDermott JR. Studies on the catabolism of NG-methylarginine, NG, N′G-dimethylarginine and NG, NG-dimethylarginine in the rabbit. Biochem J. 1976;154:179-184.
26. Schwartz S, Clare R, Devereux K, Sheung CF. Pharmacokinetics, disposition and metabolism of 546C88 (NG-methylarginine) in rat and dog. Xenobiotica. 1997;27:1259-1271.
27. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343:209-214.
28. Zhang AQ, Mitchell SC, Barrett T, Ayesh R, Smith RL. Fate of dimethylamine in man. Xenobiotica. 1994;24:379-387.
29. Zeisel SH, DaCosta KA, Fox JG. Endogenous formation of dimethylamine. Biochem J. 1985;232:403-408.
30. Kakimoto Y, Matsuoka Y, Miyake M, Konishi H. Methylated amino acid residues of proteins of brain and other organs. J Neurochem. 1975;24:893-902.
31. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99:3092-3095.
32. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002;99:13527-32.
33. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119:1533-1540.